SRR12475146
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AER6-TTM2-A-1-1-R-A742-41 | — | C | 0.843 |
| 2 | R87 | — | — | 0.832 |
| 3 | MDT-AP-1345 | Med | Medulloblastoma | 0.830 |
| 4 | SRR26320093 | — | — | 0.829 |
| 5 | SRR8942965 | — | — | 0.827 |
| 6 | R165 | — | — | 0.826 |
| 7 | 2d8478f6-41ac-47f5-ac3c-337af7245f5b | — | — | 0.824 |
| 8 | R93 | — | — | 0.818 |
| 9 | cf37eb41-0595-4a82-a65b-3058902a48d4 | — | — | 0.817 |
| 10 | TCGA-S3-AA11-01A-31R-A41B-07 | — | B | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.050 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.030 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.010 | Inavolisib | — uncovered |